Custom PEG peptides designed to improve bioavailability, stability, and pharmacokinetic performance.
Peptide PEGylation is the covalent attachment of polyethylene glycol (PEG) to a peptide to create a PEG peptide (also called a PEGylated peptide). PEGylation can improve solubility, reduce proteolysis, increase systemic exposure, and extend apparent half-life by increasing hydrodynamic radius and reducing renal clearance.
Our team performs PEG peptide conjugation as routine work within our peptide modification pipeline. Projects typically begin with three design decisions: (1) where to attach PEG (site definition), (2) how to attach PEG (method/chemistry), and (3) which PEG derivative + spacer/linker best supports the intended performance (stable vs cleavable, monodisperse vs polydisperse).
PEGylation can improve peptide bioavailability and systemic exposure by reducing clearance and proteolysis.
Site-specific PEGylation reduces heterogeneity and helps preserve receptor binding and potency.
Analytical HPLC/UPLC, SEC (as needed), and LC-MS (when feasible) confirm identity and purity.
Site-specific PEGylation attaches PEG to a defined position on the peptide (instead of random multi-site labeling). This is typically preferred for PEGylated peptides intended for pharmacology studies or therapeutic development because it improves reproducibility and helps preserve biological activity.
Common for 1:1 PEG peptide constructs when N-terminus is not part of the active pharmacophore.
High site-control using a single engineered or native Cys; standard for strict site definition.
Used when Lys placement is unique or when controlled mixtures are acceptable for early-stage work.
Additional site-definition options include C-terminal PEGylation, non-natural amino acid incorporation, and bioorthogonal click handles to achieve precise PEG placement on peptides with challenging sequences.
We support a broad menu of PEG derivatives for peptide synthesis, including monodisperse and polydisperse PEG, linear and branched PEG, and multiple reactive end groups. Below are representative options frequently requested for PEG peptide programs.
We routinely support PEG peptide synthesis using common activated PEG reagents and custom functionalized PEG when needed.
We can advise on monodisperse vs polydisperse PEG selection based on your stage, required uniformity, analytics, and target performance.
High selectivity when a single Cys is present or engineered.
Broadly used with unique handle planning to control distribution.
Bioorthogonal coupling using azide/alkyne handles.
A PEG spacer can reduce steric hindrance and preserve binding by placing PEG away from the active surface. Spacer length and chemistry are tuned to: improve flexibility, reduce masking of pharmacophores, and support manufacturability.
Selected based on whether PEG should remain permanently attached or be released in vivo.
PEGylation performance depends on a small set of controllable variables: PEG size, PEG architecture, attachment site, spacer/linker design, and PEG distribution. Our design process co-optimizes these factors to improve exposure while preserving function.
PEG can increase peptide bioavailability by reducing clearance and increasing systemic exposure.
Site and spacer selection reduce steric masking and preserve receptor binding.
PEG can improve handling and formulation robustness for challenging peptides.
Important: Increasing PEG size or density can reduce activity if PEG is positioned near key binding residues. We routinely use site-specific PEGylation + PEG spacers to maximize bioavailability while preserving function.
If decisions depend on stability or release kinetics, we can align testing to your study design.
Peptide PEGylation is not treated as a one-off bioconjugation exercise. It is a routine, in-house capability embedded in our peptide synthesis and modification workflows.
Our PEG peptide designs balance bioavailability, potency retention, and manufacturability rather than maximizing PEG size alone.
Explore additional peptide modification and conjugation capabilities that share similar design principles, purification strategies, and analytical controls.
If you are building a long‑acting peptide strategy, we can also discuss alternative half‑life extension approaches (project-dependent).
We are committed to Total Quality Management (TQM) to ensure consistent quality, traceability, and customer satisfaction across peptide synthesis and peptide modification services, including peptide PEGylation.
Each PEGylated peptide is produced using controlled procedures with in‑process monitoring and final analytical verification. Typical release analytics include HPLC/UPLC purity profiling and identity confirmation by LC‑MS when feasible, with additional methods such as SEC applied when relevant to PEG distribution or aggregation behavior.
Documentation is scaled to the intended use and program stage and may include a Certificate of Analysis (COA), method summary, and fit‑for‑purpose acceptance criteria. Our quality practices follow ISO 9001–aligned processes, with program‑appropriate controls for research, preclinical, and GMP (as needed).
Yes. We routinely provide site-specific PEGylation at the N-terminus, single cysteine, defined lysine, C-terminus, or orthogonal handles (e.g., click chemistry) to control heterogeneity and preserve activity.
Yes. We support monodisperse PEG when defined molecular weight and narrow distributions are required, as well as polydisperse PEG for discovery-stage feasibility and cost-sensitive programs.
We commonly support PEG2 through PEG40+ (and beyond) depending on architecture and availability. PEG size is selected to balance exposure, stability, and potency retention.
Yes. Cleavable linkers (e.g., ester, disulfide, enzyme-cleavable, pH-sensitive) are supported when release is required (project-dependent). Non-cleavable stable linkers are also available.
Typical characterization includes analytical HPLC/UPLC, SEC-HPLC (when relevant), and LC-MS intact mass when feasible, plus a COA and method summary.
Send the peptide sequence, any constraints (active site, residues to avoid), desired PEG size/architecture (or “recommend”), target attachment site (or “recommend”), quantity/purity, and intended use.
For the fastest quote, send your peptide sequence(s), desired PEG peptide format (PEG size/architecture), preferred attachment site (or constraints), cleavable vs non-cleavable preference, quantity/purity targets, and intended use. We’ll recommend a practical PEGylation method plus purification/QC aligned to your application.
Not sure what’s best? Share your constraints (must keep N-terminus free, avoid Lys, preserve receptor binding, etc.). We’ll propose a site-specific PEGylation plan with an appropriate PEG spacer/linker.
What happens next: Our technical team reviews requests and responds with feasibility notes, recommended PEG derivative/method options, a QC plan, and pricing aligned to your needs.
The following resources provide additional background on peptide modification strategies, PEGylation design considerations, and long-acting peptide development.
These articles are intended for educational purposes and reflect commonly used approaches in peptide research and therapeutic development.
Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.